By Finance Pulse in KeyInfo —

Neumora Therapeutics Faces 80% Stock Plunge After Drug Trial Setback

Neumora Therapeutics' navacaprant fails Phase 3 trial endpoints, causing an 80% stock value drop. Discover the impact of this significant biotech setback.

A dramatic stock chart with a sharp downward trend, overlaid with subtle molecular structures symbol
Neumora Therapeutics Faces 80% Stock Plunge After Drug Trial Setback

Neumora Therapeutics' navacaprant drug failed to meet primary and secondary endpoints in its first Phase 3 trial, leading to an 80% drop in its stock value.

Source